Evidence map›Paper›PMID 42304961›Full record

ArticleJournal of medicinal chemistry2026

On the Scope of DCAF1-Recruiting PROTACs Degrading Protein Kinases.

Janik Weckesser, Nebojša Miletić, Saran Aswathaman Sivashanmugam, Uli Ohmayer, Martin Steger, Bachuki Shashikadze, Paul Gehrtz, Andrea Unzue Lopez, Ansgar Wegener, Timo Yoshua Dietz and 11 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Janik WeckesserInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.ORCID 0000-0001-5100-2776
Nebojša MiletićInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.ORCID 0009-0001-3157-5937
Saran Aswathaman SivashanmugamInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.
Uli OhmayerNEOsphere Biotechnologies GmbH, Fraunhofer Str. 1, Martinsried 82152, Germany.
Martin StegerNEOsphere Biotechnologies GmbH, Fraunhofer Str. 1, Martinsried 82152, Germany.
Bachuki ShashikadzeNEOsphere Biotechnologies GmbH, Fraunhofer Str. 1, Martinsried 82152, Germany.
Paul GehrtzMerck Healthcare KGaA, Darmstadt 64293, Germany.
Andrea Unzue LopezMerck Healthcare KGaA, Darmstadt 64293, Germany.
Ansgar WegenerMerck Healthcare KGaA, Darmstadt 64293, Germany.
Timo Yoshua DietzMerck Healthcare KGaA, Darmstadt 64293, Germany.ORCID 0009-0000-2591-9986
Tobias HammannMerck Healthcare KGaA, Darmstadt 64293, Germany.ORCID 0009-0006-2321-9736
Ingo V HartungMerck Healthcare KGaA, Darmstadt 64293, Germany.ORCID 0000-0001-8750-679X
Lewis ElsonInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.
Václav NěmecInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.
Martin Peter SchwalmInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.ORCID 0000-0002-1252-1829
Bikash AdhikariInstitute of Biochemistry, University of Kiel, Kiel 24118, Germany.
Elmar WolfInstitute of Biochemistry, University of Kiel, Kiel 24118, Germany.ORCID 0000-0002-5299-6335
Andreas KrämerInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.
Susanne MüllerInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.ORCID 0000-0003-2402-4157
Henrik DaubNEOsphere Biotechnologies GmbH, Fraunhofer Str. 1, Martinsried 82152, Germany.
Stefan KnappInstitute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Max-von-Laue-Straße 9, Frankfurt 60438, Germany.ORCID 0000-0001-5995-6494

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteolysis-targeting chimeras (PROTACs) have emerged as a novel drug modality, but their development currently relies on a limited number of E3 ligase ligands, primarily targeting CRBN and VHL. Conversely, current validation studies on novel E3 ligase ligands are typically limited to a few highly degradable targets, like BRD4. Here, we used our previously established workflow for E3 ligase ligand validation, employing promiscuous kinase PROTACs, to evaluate the potential of recruiting DCAF1 for PROTAC development. Our study revealed the DCAF1-dependent degradation of a diverse set of kinases, which were validated in orthogonal assays. In a comparative analysis, we identified a significant overlap between the degradable kinome of DCAF1- versus CRBN-recruiting PROTACs, suggesting alternative design strategies for PROTACs using available structurally diverse DCAF1 ligands. Moreover, ubiquitinomics analysis of the PROTAC-induced ubiquitination patterns provided insight into substrate- and isoform-selective degradation. The presented data will establish DCAF1-recruiting PROTACs as a versatile design strategy for future degrader development.

Indexed as

Protein KinasesUbiquitin-Protein LigasesBromodomain Containing ProteinsHumansLigandsProteolysisProteolysis Targeting ChimeraUbiquitinationBromodomain Containing ProteinsLigandsProtein KinasesProteolysis Targeting ChimeraUbiquitin-Protein Ligases

Identifiers

PMID42304961
PMCPMC13370871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.